|Amino Acid Change||V1188L|
|Transcript ID (GRCh37/hg19)||ENST00000318493|
|Tumor Type||Primary Site|
Activating somatic mutations in the tyrosine kinase domain of MET are found in about 10–15% of sporadic papillary renal cell carcinoma (pRCC). MET mutations are predominantly associated with Type 1 pRCC tumors. The responses to foretanib an oral inhibitor of MET and other tyrosine kinases including VEGFR2, have been described in patients with papillary renal cell cancer.